Rubric Capital Management LP grew its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 25.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,680,028 shares of the company's stock after purchasing an additional 943,226 shares during the quarter. Rubric Capital Management LP owned approximately 1.23% of GoodRx worth $32,479,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the company. Millennium Management LLC boosted its stake in shares of GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company's stock valued at $32,151,000 after purchasing an additional 1,102,758 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of GoodRx during the second quarter valued at about $18,183,000. Picton Mahoney Asset Management boosted its stake in shares of GoodRx by 24.3% during the second quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company's stock valued at $4,736,000 after purchasing an additional 118,703 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company's stock valued at $3,332,000 after purchasing an additional 26,262 shares in the last quarter. Finally, Raymond James & Associates boosted its stake in shares of GoodRx by 212.6% during the third quarter. Raymond James & Associates now owns 394,006 shares of the company's stock valued at $2,734,000 after purchasing an additional 267,951 shares in the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.
GoodRx Trading Up 2.1 %
GoodRx stock traded up $0.10 during mid-day trading on Wednesday, reaching $4.86. The stock had a trading volume of 682,304 shares, compared to its average volume of 1,448,115. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The stock's 50-day simple moving average is $6.11 and its 200-day simple moving average is $7.29.
Insider Buying and Selling at GoodRx
In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.17% of the company's stock.
Analysts Set New Price Targets
A number of analysts have recently commented on GDRX shares. UBS Group cut their price target on GoodRx from $9.00 to $8.50 and set a "neutral" rating on the stock in a research note on Friday, August 9th. Raymond James upgraded GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 price objective for the company in a research report on Friday, August 9th. Barclays lowered their price objective on GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price objective on shares of GoodRx in a research report on Friday, August 16th. Finally, Citigroup lowered their price objective on GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $8.86.
View Our Latest Stock Analysis on GoodRx
GoodRx Company Profile
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Recommended Stories
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
